HROW HARROW, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1360214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.3%
TTM net income YoY-471.2%
TTM EPS YoY-484.6%
Revenue 3-yr CAGR38.5%
Net income 3-yr CAGR—
Margins
Gross margin73.5%
Operating margin-2.0%
Net margin-9.4%
FCF margin-6.7%
EBITDA margin-1.4%
Returns
ROE-74.8%
ROA-7.1%
ROIC (approx.)-3.5%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets93.5%
Debt / equity0.00x
Current ratio2.29x
Interest coverage-0.26x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $272.30M | $199.61M | $130.19M | $88.59M | $72.48M |
| Cost of revenue | $67.93M | $49.24M | $39.64M | $25.38M | $18.21M |
| Gross profit | $204.37M | $150.37M | $90.55M | $63.21M | $54.26M |
| R&D expense | $20.94M | $12.23M | $6.65M | $3.05M | $11.08M |
| SG&A expense | $152.91M | $129.06M | $83.09M | $58.24M | $41.31M |
| Operating income | $30.52M | $8.82M | $431,000 | $1.92M | $1.61M |
| Interest expense | $24.18M | $22.79M | $21.32M | $7.24M | $5.44M |
| Pretax income | -$1.37M | -$17.32M | -$23.71M | -$14.01M | -$17.87M |
| Income tax | $3.77M | $161,000 | $701,000 | $75,000 | $133,000 |
| Net income | -$5.14M | -$17.48M | -$24.41M | -$14.09M | -$18.01M |
| EBITDA | $32.43M | $10.67M | $1.96M | $3.40M | $3.33M |
| EPS (basic) | -0.14 | -0.49 | -0.75 | -0.51 | -0.69 |
| EPS (diluted) | -0.14 | -0.49 | -0.75 | -0.51 | -0.69 |
| Weighted avg. shares (diluted) | 36.76M | 35.65M | 32.62M | 27.46M | 26.76M |
| Banking | |||||
| Net interest income | — | — | — | — | -$5.44M |
| Balance sheet | |||||
| Cash & equivalents | $72.93M | $47.25M | $74.08M | $96.27M | $42.17M |
| Short-term investments | — | — | $8.68M | $5.59M | $8.50M |
| Receivables | $110.89M | $116.37M | $36.26M | $6.25M | $4.47M |
| Inventory | $13.52M | $10.70M | $10.87M | $6.54M | $4.22M |
| Current assets | $211.75M | $189.65M | $139.48M | $118.26M | $60.66M |
| PP&E, net | $3.26M | $3.73M | $3.52M | $3.49M | $3.14M |
| Goodwill | $332,000 | $332,000 | $332,000 | $332,000 | $332,000 |
| Intangibles | $175.17M | $184.95M | $159.91M | $23.73M | $15.81M |
| Total assets | $399.48M | $388.97M | $312.16M | $157.38M | $98.33M |
| Current liabilities | $96.30M | $91.34M | $49.34M | $18.63M | $9.72M |
| Long-term debt | $250.00M | $262.74M | $246.72M | $151.77M | $103.03M |
| Total debt | $250.00M | $262.74M | $246.72M | $151.77M | $103.03M |
| Total liabilities | $347.39M | $319.67M | $241.75M | $130.14M | $87.40M |
| Shareholders' equity | $52.45M | $69.65M | $70.77M | $27.59M | $11.29M |
| Net debt | $177.07M | $215.49M | $172.63M | $55.50M | $60.87M |
| Shares outstanding | 37.23M | 35.62M | 35.17M | 29.90M | 26.90M |
| Cash flow statement | |||||
| Operating cash flow | $43.86M | -$22.20M | $3.84M | $1.71M | $5.08M |
| Capital expenditure | $887,000 | $1.59M | $1.46M | $2.60M | $1.79M |
| Free cash flow | $42.98M | -$23.80M | $2.38M | -$892,000 | $3.30M |
| Investing cash flow | -$5.46M | -$33.16M | -$152.55M | -$1.74M | -$18.69M |
| Financing cash flow | -$12.72M | $28.53M | $126.53M | $54.14M | $51.47M |
| Depreciation & amortization | $1.92M | $1.85M | $1.53M | $1.48M | $1.72M |
| Stock-based compensation | $12.50M | $17.62M | $15.70M | $7.97M | $5.75M |
Free plan shows the latest 5 periods; Pro shows all 27 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.